NASDAQ:ASND - Ascendis Pharma A/S Stock Price, Forecast & News

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings data on Monday, November, 18th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.37) by $0.78. The biotechnology company earned $2.49 million during the quarter, compared to analyst estimates of $1.88 million. Ascendis Pharma A/S had a negative return on equity of 29.04% and a negative net margin of 789.80%. View Ascendis Pharma A/S's Earnings History.

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Ascendis Pharma A/S.

8 analysts have issued twelve-month target prices for Ascendis Pharma A/S's shares. Their forecasts range from $139.00 to $186.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $158.00 in the next year. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

News coverage about ASND stock has trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Ascendis Pharma A/S.

Ascendis Pharma A/S saw a decrease in short interest in December. As of December 13th, there was short interest totalling 2,130,000 shares, a decrease of 9.4% from the November 28th total of 2,350,000 shares. Based on an average trading volume of 246,600 shares, the days-to-cover ratio is presently 8.6 days. Approximately 4.9% of the company's shares are sold short. View Ascendis Pharma A/S's Current Options Chain.

Some companies that are related to Ascendis Pharma A/S include UCB (UCBJF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT) and Catalent (CTLT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include Neurocrine Biosciences (NBIX), AbbVie (ABBV), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), InVitae (NVTA), ACADIA Pharmaceuticals (ACAD), Alexion Pharmaceuticals (ALXN), Amarin (AMRN) and Arrowhead Pharmaceuticals (ARWR).

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Henry James International Management Inc. (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%).

ASND stock was sold by a variety of institutional investors in the last quarter, including Henry James International Management Inc..

ASND stock was bought by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank .

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ASND stock can currently be purchased for approximately $137.00.

Ascendis Pharma A/S has a market capitalization of $5.77 billion and generates $12.50 million in revenue each year. The biotechnology company earns $-153,650,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.View Additional Information About Ascendis Pharma A/S.

The official website for Ascendis Pharma A/S is http://www.ascendispharma.com/.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]